Human Schwann Cell-Like: Cell Line sNF96.2 

Technology #11278

Questions about this technology? Ask a Technology Manager

Download Printable PDF

David F. Muir IV
Margaret Wallace
Managed By
John Byatt
Assistant Director 352-392-8929

Cell Line Obtained From a Nervous Tumor in a Patient With Neurofibromatosis-1

Scientists at the University of Florida have developed a wide variety of monoclonal and polyclonal antibodies, cell lines, vectors and biological materials that can be used in other research projects. Anyone interested in accessing these materials via a license from the University of Florida should contact our office to make arrangements. NF1 Status: The MPNST culture sNF96.2 was derived from tumor material from a 28 year-old male NF1 patient who met diagnostic criteria. The originative tumor tissue for the sNF96.2 cell line was obtained from a recurrent mass associated with nerve in the lower leg diagnosed by histopathology as a MPNST. The portion of the tumor specimen used for tissue culture was independently characterized by immunohistopathology and confirmed as MPNST. The sNF96.2 tumor culture cells were derived from numerous passages of primary tumor material in culture until they were a homogenous Schwann cell-like population and displayed a clonal morphology immunopositive for both the cytoplasmic Schwann cell markers S100 and p75. sNF96.2 has an abnormal karyotype, complete LOH (no detection of the remaining NF1 allele) and an identified NF1 germline was identified as a base pair deletion in exon 21 (3683delC) causing a frameshift which leads to a premature stop codon prior to the ras-GAP domain (Perrin et al., manuscript submitted). In addition, somatically this tumor has LOH of the entire 17 homolog (referred to as MPNST 459T1 in Rasmussen et al. 2000, Genes Chromosomes Cancer 28:425-431). As predicted by genotyping, the sNF96.2 culture showed no full-length neurofibromin when analyzed by Western immunoblotting using polyclonal antibodies against neurofibromin (Perrin et al., manuscript submitted).